Pacira Pharmaceuticals (PCRX) PT Raised to $67 at Northland Capital Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq hits near three-month low as Amazon, Intel deepen AI capex concerns
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Price: $36.40 +0.03%
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 46 | New: 9
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 46 | New: 9
Join SI Premium – FREE
Northland Capital Markets analyst Tim Chiang raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $67.00 (from $61.00) while maintaining a Market Perform rating.
You May Also Be Interested In
- Viatris launches $36.50-per-share tender offer for Pacira BioSciences
- Eli Lilly (LLY) PT Raised to $1,600 at RBC Capital After an 'Impressive Quarter'
- First Solar (FSLR) PT Lowered to $248 at Freedom Broker
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
